Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vivos Therapeutics, Inc. - Common Stock (NQ:VVOS)

4.130 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vivos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Vivos Reports 7% Sales Drop
Via The Motley Fool
Vivos Therapeutics Unveils New Model
Via The Motley Fool
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
Unusual volume stocks in Wednesday's session
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
Earnings Outlook For Vivos Therapeutics
 
Via Benzinga
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Gapping stocks in Thursday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model &amp; Key Regulatory Milestones Provide Revenue Tailwind”
December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New... 
Via TheNewswire.com
Why Vision Marine Technologies Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For May 15, 2025
 
Via Benzinga
Earnings Scheduled For March 31, 2025
 
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices
Via Investor Brand Network
Earnings Scheduled For November 14, 2024
 
Via Benzinga
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
 
Via Benzinga
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Via Investor Brand Network
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000
 
Via Benzinga
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today
NVDA, TMUS, VVOS, SOFI, TSLA are the top trending stocks on Wednesday. 
Via Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17. 
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
Via Investor Brand Network
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024
VVOS stock results show that Vivos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.